Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies.
CNS
HER2
brain metastasis
breast cancer
lapatinib
metastatic
neratinib
pertuzumab
trastuzumab
tucatinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
03
05
2021
revised:
05
06
2021
accepted:
08
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Development of brain metastases can occur in up to 30-50% of patients with breast cancer, representing a significant impact on an individual patient in terms of survival and quality of life. Patients with HER2-positive breast cancer have an increased risk of developing brain metastases; however, screening for brain metastases is not currently recommended due to the lack of robust evidence to support survival benefit. In recent years, several novel anti-HER2 agents have led to significant improvements in the outcomes of HER2-positive metastatic breast cancer. Despite these advances, brain and leptomeningeal metastases from HER2-positive breast cancer remain a significant cause of morbidity and mortality, and their optimal management remains an unmet need. This review presents an update on the current and novel treatment strategies for patients with brain metastases from HER2-positive breast cancer and discusses the open questions in the field.
Identifiants
pubmed: 34208287
pii: cancers13122927
doi: 10.3390/cancers13122927
pmc: PMC8230933
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
JAMA Oncol. 2018 Sep 1;4(9):1214-1220
pubmed: 29955792
J Clin Oncol. 2010 Mar 1;28(7):1124-30
pubmed: 20124187
Am J Cancer Res. 2019 Oct 01;9(10):2103-2119
pubmed: 31720077
Cancer Biol Ther. 2019;20(2):192-200
pubmed: 30403909
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Cancer. 2003 Jun 15;97(12):2972-7
pubmed: 12784331
MAbs. 2011 Mar-Apr;3(2):153-60
pubmed: 21150307
Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143
pubmed: 30377778
Br J Cancer. 2010 Mar 16;102(6):995-1002
pubmed: 20179708
J Clin Oncol. 2018 Sep 20;36(27):2804-2807
pubmed: 29939840
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Cancers (Basel). 2021 Mar 03;13(5):
pubmed: 33802424
Ann Oncol. 2011 Mar;22(3):625-630
pubmed: 20724575
Neuro Oncol. 2021 Oct 1;23(10):1656-1667
pubmed: 33659980
JAMA Oncol. 2021 Jul 1;7(7):1062-1064
pubmed: 34014298
Ann Oncol. 2020 Sep;31(9):1231-1239
pubmed: 32461105
Neuro Oncol. 2019 May 6;21(5):659-668
pubmed: 30726965
Clin Cancer Res. 2019 Apr 15;25(8):2433-2441
pubmed: 30593513
Clin Cancer Res. 2019 Jul 1;25(13):3946-3953
pubmed: 30940654
Lancet Oncol. 2017 Nov;18(11):1512-1522
pubmed: 29037983
J Neurooncol. 2017 Jan;131(1):69-72
pubmed: 27995546
Lancet Oncol. 2018 Mar;19(3):323-336
pubmed: 29433963
Breast Cancer Res Treat. 2014 Aug;146(3):477-86
pubmed: 25038877
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
Breast Cancer Res Treat. 2016 Jun;157(2):307-318
pubmed: 27167986
J Clin Oncol. 2017 Sep 10;35(26):3030-3038
pubmed: 28437161
J Neurooncol. 2017 Sep;134(2):443-451
pubmed: 28687923
Eur J Cancer. 2020 Jan;125:22-30
pubmed: 31835235
Ann Oncol. 2013 Jun;24(6):1526-33
pubmed: 23463626
Ann Oncol. 2020 Oct;31(10):1350-1358
pubmed: 32634611
Clin Cancer Res. 2009 Feb 15;15(4):1452-9
pubmed: 19228746
Neuro Oncol. 2017 Jan;19(1):i1-i24
pubmed: 28031389
Cold Spring Harb Perspect Med. 2020 Jun 1;10(6):
pubmed: 31615863
Oncologist. 2020 Feb;25(2):e214-e222
pubmed: 32043771
Breast Cancer Res Treat. 2013 Nov;142(2):405-14
pubmed: 24197661
Breast. 2018 Oct;41:137-143
pubmed: 30092500
Clin Pharmacol Ther. 2010 May;87(5):586-92
pubmed: 20357763
Crit Rev Oncol Hematol. 2019 Mar;135:85-94
pubmed: 30819451
J Clin Oncol. 2020 Aug 10;38(23):2610-2619
pubmed: 32468955
Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412
pubmed: 25561720
J Clin Oncol. 2019 May 1;37(13):1081-1089
pubmed: 30860945
Am J Cancer Res. 2015 Apr 15;5(5):1580-93
pubmed: 26175929
Breast Cancer Res Treat. 2015 Jan;149(1):277-84
pubmed: 25528021
Ann Oncol. 2006 Jun;17(6):935-44
pubmed: 16603601
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):631-6
pubmed: 20932686
J Clin Oncol. 2015 May 10;33(14):1564-73
pubmed: 25605838
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
J Neurosurg. 2019 Feb 8;132(2):503-511
pubmed: 30738402
Lancet Oncol. 2013 Jan;14(1):64-71
pubmed: 23122784
Ann Oncol. 2014 Jun;25(6):1116-21
pubmed: 24685829
Cancer Treat Rev. 2020 Aug;88:102046
pubmed: 32599393
Anticancer Drugs. 2007 Jan;18(1):23-8
pubmed: 17159499
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Br J Cancer. 2009 Mar 24;100(6):894-900
pubmed: 19240719
Clin Exp Metastasis. 2015 Oct;32(7):729-37
pubmed: 26303828
J Clin Oncol. 2021 Aug 20;39(24):2667-2675
pubmed: 33945296
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
Nat Rev Neurol. 2020 Oct;16(10):557-574
pubmed: 32873927
Ann Oncol. 2008 Jul;19(7):1242-1248
pubmed: 18334512
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Oncologist. 2010;15(9):924-34
pubmed: 20736298
Clin Cancer Res. 2011 Jul 15;17(14):4834-43
pubmed: 21768129
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Ann Transl Med. 2018 May;6(9):163
pubmed: 29911111
Ann Oncol. 2015 Jan;26(1):113-119
pubmed: 25355722
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
Eur J Cancer. 2017 Oct;84:141-148
pubmed: 28810186
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
J Clin Oncol. 2019 Oct 10;37(29):2610-2619
pubmed: 31430226
Breast Cancer Res Treat. 2019 Sep;177(2):277-294
pubmed: 31209686
Nat Med. 2013 Dec;19(12):1584-96
pubmed: 24309662
JAMA Oncol. 2016 Dec 01;2(12):1557-1564
pubmed: 27078022
Cancer Res Treat. 2020 Oct;52(4):1059-1066
pubmed: 32340083
Oncologist. 2008 Oct;13(10):1114-9
pubmed: 18849320
Breast Cancer Res Treat. 2017 Aug;164(3):581-591
pubmed: 28493046
Expert Opin Biol Ther. 2021 Feb;21(2):127-133
pubmed: 33238772
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716